Skip to content
Screener

Innoviva, Inc. INVA Financing Cash Flow

Financing Cash Flow at other companies

Pfizer logo
PfizerPFE
-$2.86B+45.4%
Merck & Co. logo
Merck & Co.MRK
-$2.98B+48.2%
AbbVie logo
AbbVieABBV
$919M+173%
Insmed logo
InsmedINSM
$27.18M-96.8%
Savara logo
SavaraSVRA
-$195K-108%
ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
$54.87M+712%

Other financials

Income statement

See full
Revenue$119.6M+19.3%
Gross profit$90.6M+9.0%
Operating income$50.9M+4.3%
Net income-$83.4M-231%
EPS (diluted)-$1.14-248%

Balance sheet

See full
Cash & equivalents$570.4M+43.5%
Total debt$269.7M-40.2%
Total equity$1.2B
Total assets$1.7B+27.7%

Cash flow

See full
Operating cash flow$52.0M+17.9%
CapEx$429.0K
Free cash flow$51.5M+16.9%

Valuation

See full
Market cap$1.49B+20.6%
Enterprise value$1.19B-7.6%
P/E4.2×-27.8×
P/S3.4×+0.1×

Profitability

See full
Gross margin72.2%-10.9pp
Operating margin36.9%-10.7pp
Net margin81.2%+70.8pp
FCF margin43.1%-11.1pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio16×+13.4×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Innoviva, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:26 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335235
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Cash flows from financing activities
Repurchase of common stock(51,314)
Repurchase of shares to satisfy tax withholding(252)(91)
Proceeds from issuances of common stock, net2,0151,521
Net cash provided by (used in) financing activities(49,551)1,430
Net increase in cash and cash equivalents19,44792,568
Cash and cash equivalents at beginning of period550,941304,964
Cash and cash equivalents at end of period$570,388$397,532

Item 1. Financial Statements

FAQ

What is Innoviva, Inc.'s financing cash flow?
Innoviva, Inc. (INVA) reported financing cash flow of -$29.41M in Q2 2026.
How has Innoviva, Inc.'s financing cash flow changed year-over-year?
Innoviva, Inc.'s financing cash flow decreased by 2458.1% year-over-year, from $1.25M to -$29.41M.
What is the long-term trend for Innoviva, Inc.'s financing cash flow?
Over 2 years (2021 to 2023), Innoviva, Inc.'s financing cash flow has grown at a -38.4% compound annual growth rate (CAGR), from -$452.5M to -$171.84M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Innoviva, Inc.'s financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude